Cargando…
A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
It has been suggested that soluble urokinase receptor (suPAR) is a causative circulating factor for and a biomarker of focal and segmental glomerulosclerosis (FSGS). Here we undertook validation of these assumptions in both mouse and human models. Injection of recombinant suPAR in wild-type mice did...
Autores principales: | Spinale, Joann M., Mariani, Laura H., Kapoor, Shiv, Zhang, Jidong, Weyant, Robert, Song, Peter X., Wong, Hetty N., Troost, Jonathan P., Gadegbeku, Crystal A., Gipson, Debbie S., Kretzler, Matthias, Nihalani, Deepak, Holzman, Lawrence B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344842/ https://www.ncbi.nlm.nih.gov/pubmed/25354239 http://dx.doi.org/10.1038/ki.2014.346 |
Ejemplares similares
-
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017) -
Reassessing the Reassessment of suPAR in Glomerular Disease
por: Meijers, Björn K. I., et al.
Publicado: (2015) -
From lactate to soluble urokinase plasminogen activator receptor: The journey for ideal cardiac biomarker: Are we there in 2016?
por: Kapoor, Poonam Malhotra
Publicado: (2016) -
Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014) -
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)